Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Anemia × LY2787106 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Interventions

peginesatide 2 hematide 2 Lenalidomide 2 venetoclax 1 trametinib 1 ruxolitinib 1 reolysin 1 regorafenib 1 ponatinib 1 pertuzumab 1 pembrolizumab 1 palbociclib 1 olaparib 1 neratinib 1 lorlatinib 1 lenvatinib 1 idelalisib 1 enzalutamide 1 entrectinib 1 enasidenib 1 durvalumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 dehydroftorafur 1 darolutamide 1 dacomitinib 1 dabrafenib 1 copanlisib 1 cobimetinib 1 carfilzomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01340976 2018-10-03

A Phase 1 Study of LY2787106 in Cancer and Anemia

Eli Lilly and Company

Phase 1 Completed

33 enrolled 18 charts

Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡